Tirzepatide for obstructive sleep apnoea: what the evidence shows

Step 1, understanding why these two conditions are so closely linked

If you have been told you have obstructive sleep apnoea and are also carrying significant excess weight, you are far from alone, and the relationship between the two is not coincidental. Fatty tissue deposited around the neck and upper airway physically reduces the space through which air can pass during sleep; the chest wall and diaphragm also work harder when abdominal fat increases breathing effort. The result is repeated partial or complete airway collapse, the apnoea events that a CPAP machine is designed to compensate for.

What makes this particularly difficult is the feedback loop. Poor sleep from OSA elevates cortisol and suppresses leptin, the satiety hormone, which can increase appetite and make weight management harder independently of willpower or diet. For many people, both problems worsen quietly together over years before a formal diagnosis of either arrives. Tirzepatide, as a dual GIP and GLP-1 receptor agonist, acts on the appetite-signalling system directly, and researchers have studied whether reducing body weight through this mechanism translates into measurable OSA improvement, a question our page on Mounjaro and sleep apnea explores in detail.

You can read more about the specific mechanism behind this effect on our page exploring how Mounjaro works for sleep apnea, and if you want to understand the tirzepatide side of that picture, our dedicated page on how tirzepatide helps sleep apnea takes you through the pharmacology in plain terms.

Step 2, what the SURMOUNT-OSA trials found

The most direct clinical evidence comes from the SURMOUNT-OSA programme, a pair of phase 3 randomised controlled trials involving adults with moderate-to-severe obstructive sleep apnoea and obesity. One trial included participants using CPAP; the other included those unable or unwilling to use it. Both arms tested tirzepatide at 10mg or 15mg maintenance doses against placebo over 52 weeks.

The primary outcome measure was the apnoea-hypopnoea index (the number of breathing disruptions per hour of sleep) and the results were substantial. Participants receiving tirzepatide saw their AHI fall by around 25 to 30 events per hour on average, compared with roughly 5 events per hour in the placebo group. Average body weight fell by around 20% in the tirzepatide arm. The trial also measured patient-reported outcomes including sleepiness scores and sleep quality, where improvements were reported alongside the AHI changes. The NICE technology appraisal of tirzepatide (TA1026) references the broader body of evidence supporting its use in adults with obesity and weight-related conditions, of which OSA is a recognised example.

It is worth knowing that these were research settings with closely monitored participants. Individual results vary, and whether tirzepatide is right for your situation depends on a full clinical picture that a prescriber reviews with you.

Step 3, what this means for eligibility and the role of a prescriber

Tirzepatide's UK licence covers weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition. Obstructive sleep apnoea is one of the conditions that can count toward that threshold, a detail worth understanding if your BMI sits in the 27–29 range and OSA is your primary concern alongside weight.

Having OSA does not automatically mean tirzepatide will be prescribed. A prescriber looks at the whole picture: your BMI, other health conditions, current medicines, and whether the expected benefits outweigh any risks for you specifically. The treatment starts at a low tolerability dose and is increased gradually under clinical supervision, the schedule described in the full Mounjaro treatment guide gives useful background on how that process works. People sometimes ask whether OSA alone is sufficient grounds for treatment; the honest answer is that it depends on the rest of your profile, and that question is precisely what a clinical assessment is for.

It is also sensible to keep using any CPAP or other OSA management your sleep clinic has recommended while weight-loss treatment is underway. Tirzepatide does not replace those interventions in the short term; the AHI improvements seen in trials took the full treatment period to accumulate, and our page covering Mounjaro and bowel obstruction is a useful reminder of why reporting any new or unusual abdominal symptoms to your prescriber promptly matters throughout treatment. Discuss the timing of any changes to your sleep therapy with both your prescriber and your sleep specialist.

Step 4, practical considerations before you start

The most common side effects of tirzepatide are gastrointestinal: nausea, loose stools, constipation, and indigestion tend to be most noticeable in the first few weeks or after a dose increase, and most people find they settle considerably over time. The NHS tirzepatide medicines page lists what to watch for and when to contact a doctor. Anyone experiencing severe, persistent abdominal pain that spreads toward the back should seek medical attention promptly, given the known association between GLP-1 medicines and acute pancreatitis, as highlighted in a 2026 MHRA safety communication.

Tirzepatide is not recommended during pregnancy, breastfeeding, or for anyone under 18. Women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, as absorption of the pill may be reduced. That is a detail prescribers discuss at the point of assessment rather than something to manage alone.

If you are considering the cost of private treatment, our page on Mounjaro pricing in the UK explains how the private market works and what a legitimate price typically includes. For a broader overview of all weight-loss treatment options available through our pharmacy, the weight-loss treatment overview is a helpful starting point. Our clinical team reviews every consultation personally, the same day it is submitted.